Shots:
- Roche has reported data from the ongoing OLE P-III (Portal) study of Susvimo (port delivery platform with Lucentis) for the treatment of nAMD
- The P-III (Archway) trial assessed Susvimo (Q6W refill, n=248) vs Lucentis (QM, IVT, n=168) in 415 nAMD pts responsive to prior anti-VEGF therapy; 352 entered the Portal OLE study, where 132 Lucentis-treated pts switched to Susvimo with Q6M refills (IVT-Susvimo arm)
- 5yr. data showed sustained disease control & retinal drying in pts who began treatment with near-peak vision after ~5 IVT per SoC. BCVA declined from 74.4 to 67.6 (Susvimo) & 76.3 to 68.6 (IVT-Susvimo), with 50% retaining >20/40 vision & CST reductions of 1µm & 10.3µm, respectively; data were presented at ASRS 2025
Ref: GlobeNewsWire| Image: Roche| Press Release
Related News:- Roche’ Elecsys pTau181 Test Receives the European CE Mark Approval to Rule Out Alzheimer’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
